Naloxon Hcl Accord (Naloxone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Naloxon Hcl Accord, is an opioid antagonist presented as an injectable solution for intravenous use. It rapidly reverses opioid‑induced respiratory depression and sedation in patients experiencing an opioid overdose and is indicated for emergency treatment in pre‑hospital and hospital settings.

GNH USA supplies Naloxon Hcl Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation for global distribution.

Naloxone Hydrochloride acts on the opioid receptor pathway to counteract opioid toxicity. - Opioid overdose: quickly restores normal breathing and consciousness in patients with life‑threatening opioid intoxication. - Opioid‑induced respiratory depression: reverses suppressed respiration during procedural sedation or chronic opioid therapy. - Emergency opioid toxicity: provides immediate antagonism in pre‑hospital or hospital emergency settings.

Naloxone is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Injection site pain: mild discomfort at the site of intravenous administration. - Nausea: transient feeling of queasiness. - Vomiting: occasional emesis following reversal of opioid effects. - Sweating: increased perspiration during recovery. - Restlessness: brief agitation as opioid effects wear off. - Headache: mild headache in some patients.

Serious or Rare Side Effects: - Acute withdrawal syndrome: severe agitation, hypertension, tachycardia, or seizures in opioid‑dependent individuals. - Cardiac arrhythmias: rare cases of irregular heart rhythm. - Hypotension: sudden drop in blood pressure. - Pulmonary edema: rare fluid accumulation in the lungs. - Anaphylaxis: severe allergic reaction requiring immediate medical attention.

Naloxone should be used with awareness of specific safety considerations. - Patient assessment: evaluate for opioid dependence and potential for precipitated withdrawal. - Monitoring: observe vital signs and respiratory status continuously after administration. - Contraindications: avoid use in patients with known hypersensitivity to naloxone. - Co‑administration: be prepared to provide supportive care for severe withdrawal symptoms. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naloxone may interact with other medications that affect the central nervous system.

Major Interactions (Avoid): - Opioid agonists: concurrent high‑dose opioids can diminish reversal effectiveness. - Central nervous system depressants: may mask residual sedation after naloxone.

Moderate Interactions (Monitor Closely): - Benzodiazepines: monitor for additive respiratory depression. - Tricyclic antidepressants: watch for altered cardiovascular response. - Anticholinergic agents: assess for increased risk of agitation or delirium.